Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258524 | 1.00 | ALDH1A1 (0.40) | ALDH1A1POLBLMNAHTTRAB9A | |
| SCHEMBL13609524 | 0.96 | ALDH1A1 (0.39) | ALDH1A1POLBLMNAHTTRAB9A | |
| SCHEMBL13773434 | 0.91 | GCK (0.45) | ALDH1A1POLBHTTGCKKMT2A | |
| SCHEMBL2652530 | 0.91 | GCK (0.45) | ALDH1A1POLBHTTGCKKMT2A | |
| SCHEMBL2652346 | 0.90 | GCK (0.43) | ALDH1A1POLBHTTRAB9ANPC1 | |
| SCHEMBL1581584 | 0.88 | KMT2A (0.44) | ALDH1A1POLBLMNAHTTGCK | |
| SCHEMBL1581586 | 0.88 | KMT2A (0.44) | ALDH1A1POLBLMNAHTTGCK | |
| SCHEMBL2646100 | 0.88 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAHTTRAB9A | |
| SCHEMBL2646097 | 0.88 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAHTTRAB9A | |
| SCHEMBL2513636 | 0.87 | HTT (0.35) | ALDH1A1POLBHTTRAB9AGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | GK, GCKR, AK2 | ALDH1A1 1817/4885POLB 3748/4885LMNA 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.